Putting genomics into practice: A new analysis casts doubt on the clinical utility of CYP2C19 genotype testing to help guide antiplatelet prescribing

BMJ (Online)

Volumn 343, Issue 7819, 2011, Pages

  Holmes, Michael V ^a   Casas, Juan P ^b   Hingorani, Aroon D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; DNA SEQUENCE; DRUG RESPONSE; EDITORIAL; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN GENOME; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; NOTE; THROMBOEMBOLISM;

ARYL HYDROCARBON HYDROXYLASES; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; THROMBOEMBOLISM; TICLOPIDINE;

EID: 84859009640     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4953     Document Type: Editorial

References (12)

1. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
3. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. National Human Genome Research Institute. www.genome.gov/26525384.
4. Hingorani AD, Shah T, Kumari M, Sofat R, Smeeth L. Translating genomics into improved healthcare. BMJ 2010;341:c5945.
5. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010;362:986-93.
6. Holmes MV, Harrison S, Talmud PJ, Hingorani AD, Humphries SE. Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol 2011;8:207-21.
7. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-69. (Pubitemid 351556063)
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
10. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009;4:e7960.
11. Food and Drug Administration. Drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010. www.fda.gov/drugs/drugsafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm.
12. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. 33rd Annual San Antonio Breast Cancer Symposium, 2010:S1-7. www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L-1093.